We are live on
!
Find out more
AVM
Arch Venture Management Portfolio holdings
AUM
$677M
1-Year Est. Return
322.07%
This Fund
S&P 500
This Quarter
Est. Return
+7.53%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$162M
AUM Growth
-$45.2M
(-22%)
Cap. Flow
-$61.7M
Cap. Flow
% of AUM
-38.13%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
1
Closed
2
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Denali Therapeutics
DNLI
|
+$52.7M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$5.45M |
| 3 |
Natera
NTRA
|
+$3.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EQRX
1
DELISTED
EQRx, Inc. Common Stock
EQRX
| $67.6M | 41.73% |
36,335,375
| – | – |
|
|
VERV
2
DELISTED
Verve Therapeutics
VERV
| $37.7M | 23.26% |
2,008,809
| – | – |
|
3
Erasca
ERAS
$6.66B
| $30.5M | 18.84% |
11,055,554
| – | – |
|
|
4
Denali Therapeutics
DNLI
$3.7B
| $20.5M | 12.64% |
693,749
-1,875,000
| -73% | -$52.7M |
|
|
OMIC
5
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $3.15M | 1.95% |
126,631
| – | – |
|
|
UBX
6
DELISTED
Unity Biotechnology
UBX
| $2.56M | 1.58% |
1,004,817
| – | – |
|
|
7
Natera
NTRA
$37.8B
| – | – |
-64,441
| Closed | -$3.58M |
|
|
KRTX
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-30,000
| Closed | -$5.45M |
|
Similar funds
NI
MMPW
JC
NCM
TWM
DLIC
REAM
MCO
Arch Venture Management's Q2 2023 Portfolio in Review
As of Q2 2023, Arch Venture Management held 8 positions worth $162M, down 22% from $207M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Arch Venture Management withdrew a net $61.7M in Q2 2023, closing 2 positions and reducing 1 holding. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $5.45M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Arch Venture Management's biggest Q2 2023 reduction was Denali Therapeutics, cutting an estimated $52.7M.
- Arch Venture Management fully exited Karuna Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $5.45M.
- Arch Venture Management's ten largest holdings make up 100% of its $162M portfolio in Q2 2023.
- Arch Venture Management opened 0 new positions and closed 2 in Q2 2023.
- Arch Venture Management's portfolio value fell 22% quarter-over-quarter to $162M.
Based on Arch Venture Management's 13F filing for Q2 2023, filed 9 Aug 2023.